– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can pote...
Astellas Pharma Inc. [TSE: 4503, President and CEO: Naoki Okamura, "Astellas"] and Audax Biosciences Pty Ltd ("Audax") announced that they have ent...
Powered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD,...
ASTRIDE trial for first-line ES-SCLC demonstrated favorable median overall survival in serplulimab with chemotherapy versus atezo...
Late-breaking results to be presented in an oral presentation at ESMO 2026 PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER...
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42%...
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted...
82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer t...
Objective responses observed across eight distinct tumor types, including breast, colorectal, endometrial, gastroesophageal junction,...
Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable...
BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-nega...
Spotlight Medical, a company developing AI-powered prognostic tests in oncology, announced results from an independent evaluation of myStage Dx, its CE-IVD...
IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy so...
Topline results to be presented by Federico Cappuzzo, MD, PhD, on October 25, 2026, at the Annual Meeting of the European Society for Medical Oncology (E...
© 2026 Biopharma Boardroom. All Rights Reserved.
